[{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TL-895","moa":"BTK\/FLT3","graph1":"Oncology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Kartos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TL-895","moa":"BTK\/FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telios Pharma \/ Kartos Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Telios Pharma \/ Kartos Therapeutics"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TL-895","moa":"BTK\/FLT3","graph1":"Oncology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TL-895","moa":"BTK\/FLT3","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Kartos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Navtemadlin","moa":"Tumour suppressor p53\/oncoprotein Mdm2","graph1":"Oncology","graph2":"Phase III","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telios Pharma \/ Telios Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Telios Pharma \/ Telios Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Telios Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : TL-925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Allergic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 13, 2024

                          Lead Product(s) : Choline

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : TL-925, a first-in-class topical Bruton’s tyrosine kinase (BTK) inhibitor, it is being investigated for the treament of individuals with moderate to severe dry eye disease (DED).

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 07, 2024

                          Lead Product(s) : Choline

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : TL-925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Allergic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 05, 2024

                          Lead Product(s) : Choline

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : TL-925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 26, 2024

                          Lead Product(s) : Choline

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : TL-925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Allergic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 01, 2023

                          Lead Product(s) : Choline

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : TL-925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 27, 2023

                          Lead Product(s) : Choline

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : TL-895 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Primary Myelofibrosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 15, 2022

                          Lead Product(s) : TL-895

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : TL-895 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 16, 2020

                          Lead Product(s) : TL-895

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Kartos Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : TL-895 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Primary Myelofibrosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 07, 2020

                          Lead Product(s) : TL-895

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : KRT-232 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Primary Myelofibrosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 23, 2020

                          Lead Product(s) : Navtemadlin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Kartos Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank